suggests that if we adopt WHO's criterion that an intervention is 'cost -effective' if ICER (in QALY) is between 1 and 3 times of GDP per capita, then PCV-7 vaccination programme would be an efficient use of finite resources in healthcare from the societal perspective, regardless of the co-payment level [10] . Furthermore, the study shows that if full subsidy is provided for the vaccination programme, the level of budget impact is less than ¥11,000,000 (US$137,500; US$1 = ¥80, based on the average exchange rate of 2012) for a municipality with 1,000 birth cohort in the 1st year, and 2nd to 5th year birth cohort proportional to the birth cohort population of estimated future population.
Introduction
The 7-valent pneumococcal conjugate vaccine (PCV -7) was firstly approved in the USA in 2000 for the prevention of diseases caused by Streptococcus pneumoniae (pneumococcus) among infants and young children. In 2007, WHO recommended the vaccine to be incorporated into national childhood immunisation programmes in every country [1] . In 2009, two pneumococcal vaccines with extended serotype coverage, 10-valent (PCV-10) and 13-valent (PCV-13), were introduced, and since then, they have been gradually replacing PCV-7 [2] . The PCV-10 conjugates to non-typable Haemophilus influenza carrier protein, while PCV-13 conjugates to the same carrier protein (CRM197) as PCV-7. In order to support the adoption of PCV-10 or PCV-13, cost-effectiveness studies have been performed in various countries. In general, results of these studies have demonstrated that the use of PCV-10 or PCV-13 is cost-effective or cost saving compared to PCV-7 vaccination programme in prevention of the disease caused by Streptococcus pneumoniae (S. pneumoniae) [3] [4] [5] [6] .
In Japan, PCV-7 was approved on October 26, 2009. The government disbursed a budget to encourage municipalities in launching a public 3+1 dose vaccination programme (3 primary doses and 1 booster dose) on November 26, 2010, which will continue until March 31, 2013 . Therefore, currently all municipalities give subsidies to PCV-7 vaccinees. The attainable vaccination rate for Japanese infants is considered to be about 60%, according to the ''Provisional Special Fund for the Urgent Promotion of Vaccination against Such Diseases as Cervical Cancer'' by the government in 2011. A study group of ten health institutions and affiliated paediatricians have reported that there was a decrease in invasive pneumococcal diseases (from 333 cases in 2010 to 113 cases in 2011) after the introduction of PCV -7 [7] . As to PCV-10 and PCV-13, both are not yet available in Japan, while the latter is now under the process of approval and experts have expressed their expectations [8] .
The possible availability of PCV-13 raises the need to evaluate effective ways in protecting the birth cohort from pneumococcal -related diseases in Japan.
It is said that there are five hurdles to overcom e in the diffusion process of new health intervention: quality, safety, efficacy, cost -effectiveness and affordability [9] .
In regards to the cost-effectiveness and affordability of PCV-7 vaccination programme, our recently published economic evaluation of using PCV-7 to the birth cohort in Japan by child [21] , multiplied by the "proportion of clinically diagnosed AOM episodes due to pneumococcus (34.1%)" [22] ; of hospitalised community acquired pneumonia (CAP) are from a retrospective study of 18 hospitals with paediatric wards in Chiba city, Japan [23] . Proportions of meningitis that result ed in hearing impairment or neurological sequelae are from Kamiya et al. [20] and Iwata et al. [24] . Case fatality rates of meningitis and of bacteraemia are also from Kamiya et al. [20] ; of hospitalised pneumonia are estimated from Patient survey [25] and Vital statistics [26] . Deaths from causes other than the above diseases are also from the Vital statistics [26]. All these rates are shown in Table 1 .
Vaccine effectiveness

Direct effect
The vaccine effectiveness (VEs) of PCV-7 against vaccine-serotype-IPD (including bacteraemia and meningitis), vaccine-serotype-AOM, and hosiptalised radiograph-comfirmed pneumonia among children under 2 years old are 80%, 54%, and 27%, respectively, based on the systematic review reported by the Cochrane Collaboration [27, 28] . The VEs of PCV-13 are not available at the time of this study.
Based on the immunogenicity data, we assume PCV-13 is as immunogenic as PCV-7
for common serotypes and has comparable levels of antibody for serotypes unique to PCV-13 [2, 18, 19] . Proportion of IDP episodes due to PCV-7/PCV-13 serotype is assumed as 68.5%/80.9% [7] ; of hospitalised community acquired pneumonia (CAP) episodes, 66.7%/81.0% [23] ; of AOM ep isodes, 68,2%/86.0%, for 0 to <3 years old, and 48,5%/77.9% fir 3 to <5 years old [29] . The VEs against IPD and AOM are of specific vaccine serotypes only, therefore, they are multiplied by the proportion of relevant disease episodes due to PCV-7/PCV-13 serotypes to adjust to our disease model, while the VEs against hospitalised pneumonia are not of specific vaccine serotypes, and therefore there is no need to adjust. For those aged over 2 and under 5 years, the VEs against IPD and hospitalised pneumonia are assumed to decline by 3% annually for both PCV-7 and PCV-13 [30] .
All these data are shown in Table 1 .
No efficacy data against otitis media were available for serotypes 1, 3, 5, 6A, 7F, and 19A from the package insert of Prevenar 13® (brand name of PCV-13) sold in the US [31] . Therefore, we set two base-cases for analyses: "Base-case A", which assumes that the prevention of AOM by PCV-13 is limited to the seven serotypes of PCV-7 only; and "Base-case B", which assumes that the prevention of AOM by PCV-13
is straightforwardly extended to cover non-PCV-7 serotypes.
Indirect effects
We do not consider the net indirect vaccine effect (herd protection minus serotype replacement effect) in our base-case analysis, but conduct four scenario analyses by assuming different net indirect effects among children aged under 5 years old as observed in European countries and the US. Assumptions made for each scenario and two base-cases are shown in Table 2 . The net indirect effect in non-vaccinated children older than 5 years old is not considered in the scenario analyses because of the discrepancies among reports from previous studies [ 32] . In the US, indirect effects was observed among adults after the nationwide implementation of PCV-7 in 2000, while in European countres, such as Spain, France, and the UK, no overall reduction of IPD incidences were observed among adults even after three years of introduction in routine vaccination [32] . Rozenbaum indicates that possible factors responsible for these differences may inclu de the vaccine-serotype coverage, and/or implemented vaccination schedules, and/or antibiotic resistance rates, and/or pneumococcal disease incidences prior to vaccination.
Costing
From the societal perspective, costing should cover the opportunity costs borne by various economic entities in the society [33] . In the context of this study, the amount of direct payments costs borne by municipal authorities, vaccinees, patients and social insurers are considered, while indirect costs of vaccination programme are not included, because it is assumed that the programme is built within the public health services infrastructure. Therefore, costs of vaccination, treatment costs of pneumococcal-related diseases and costs associated to care-giver's lost productivity, such as accompanying a child for vaccination, for medical treatment, or to take care of a child with sequelae, are counted. Productivity loss due to mortality or morbidity is not included, as including this into cost-effectiveness analysis may be argued as double counting while survived cases are incorporated in the utility weights and disease duration in calculating QALYs [33] .
Direct medical costs
The vaccination cost per a shot of PCV-7 is assumed at ¥10,000 (US$125) [10] ;
per a shot of PCV-13 is assumed at 1.3 times that of PCV-7 based on the report from "The Pharma Letter" [34] . Treatment costs per episode of survived/fatal bacteraemia , survived/fatal meningitis, and long-term treatment costs for an individual with hearing impairment or neurological sequelae are according to Iwata et al. [24] . Treatment costs per episode of pneumonia caused by S. pneumoniae are according to Ishiwada et al. [35] . Treatment costs per episode of AOM are the weighted average of simple and complex cases reported b y Yamanaka et al. [21] . The proportions of complex cases are: 37%, 49%, 25%, 19%, and 14%, for children aged 0 to <1, 1 to <2, 2 to <3, 3 to <4, and 4 to <5, respectively [21] . All these costs are shown in Table 3 .
Productivity loss by care -giver
Under the context of this study, productivity loss per disease episode or per shot is valued as a product of care-giver's absent working hours from paid employment (8 working hours/day) and an average hourly wage, ¥1,328 (US$17), of Japanese women labourers [36] . Productivity loss of a care-giver to accompany a child for one uptake of vaccine is assumed as a half of a day (4h) when uptaking PCV-7 or PCV-13 alone, 1/2×4h when uptaking simultaneously with Hib vaccine. 1/2×4h is assumed because
Hib vaccination programme was introduced on the same day as PCV-7 vaccination programme in Japan, and therefore, 4h of productivity loss should be shared equally in simultaneous uptake of PCV-7/PCV-13 and Hib vaccine. And 0h, when uptaking simultaneously with one other listed vaccine, because it can be assumed that no incremental productivity loss occurs to uptake PCV-7/PCV13 in particular. As to the productivity loss per disease episode, the frequency of outpatient visits and the number of hospitalisation days of a meningitis episode are from Yamanaka et al. [21] ; of a pneumonia episode are from Ishiwada [35] . We assume 4 absent working hours for one outpatient visit and 8 absent working hours for one hospitalised day. The average absent working hours of an AOM episode are the weighted average of simple and complex AOM derived from Yamanaka et al. [21] . We assume that the absent working hours of a care-giver to take care of one child with hearing impairment or neurological sequelae is 8 hours per day until the child is admitted to special support education system, which is at age 6 in Japan.
Discounting
Costs and outcomes were discounted at a rate of 3% [33] .
Scenario analyses, sensitivity analyses, and probabilistic analyses
In order to assess the impact of herd effects on outcomes of PCV -7/PCV-13 vaccination, scenario analyses, which assume four different net indirect effects in non-vaccinated children aged under 5 years old ( Table 2) We also conduct a thousand times Monte Carlo simulation, i.e., probabilistic analyses, for which VEs are assumed to have an equilateral triangle distribution corresponding to the range tested in one way sensitivity analyses. Other variables are fixed at their base-case values.
Results
Avoided cases
The estimated disease cases avoided by PCV -7/PCV-13 vaccination programme compared with no programme for 100,000 birth cohort in the five year period are as 
Cost, effectiveness, and cost-effectiveness
Given the purpose of this study, the description should focus on the comparison between PCV-13 programme and PCV-7 programme. The results of the comparison between PCV-7/PCV-13 against no-programme are shown in Table 4 as reference. programme is 99.0%/42.5%, and the probability of ICER to be less than ¥5,000,000 (US$62,500) per QALY is 99.9%/95.0%.
Uncertainty analyses
Discussion
We estimate the cost-effectiveness of replacing the current PCV-7 vaccination programme with PCV-13 vaccination programme, and the effectiveness of PCV-13 is calculated based on the effects of PCV-7 and the serotype coverage of PCV-13 compared to PCV-7, as done in other studies [4] [5] [6] .
Our base-case analyses, which sets the cost of PCV -13 per shot at 1. In Base-case B, the ICERs in QALY of our base-case analyses, scenario analyses and sensitivity analyses are all less than a willingness-to-pay threshold suggested for healthcare intervention, i.e., ¥5,000,000 (US$62,500) per QALY gained [34] , and are under WHO's cost-effective criterion for intervention, i.e., less than 3 times of GDP per capita (≑¥11,000,000 or US$137,500 in Japan) [39] . Therefore, when we consider the "value for money", the replacement of PCV-7 with PCV-13 vaccination programme would be a socially acceptable option in Japan from the viewpoint of health economics.
On the other hand, in Base-case A, unless the cost of one PCV-13 shot is equal to or less than ¥11,000 (US$138), the ICERs would all be over ¥11,000,000 (US$137,500).
Therefore the replacement is not considered a socially acceptable option in Japan.
A recent study reported the cost -effectiveness ratio (CER) of Rotavirus vaccination programme in Japan , of which ratio was ¥9.8 million per QALY. [40] This is larger than our CERs of PCV-7 or PCV-13, which is ¥6.4 million or ¥9.0 million per QALY, respectively. Several studies from overseas reported on the cost-effectiveness of introducing PCV-13. Among them, some compared PCV-7 and PCV-13 with no-programme from the societal perspective and found PCV -13 is more cost-effective than PCV-7 with or without considering net-indirect effect [6, 32] . By taking the cost-effective ratios (CERs) of PCV-7/PCV-13 vaccination programme and comparing them to that of no-programme, our study yields a result that is consistent with those previous studies. On the other hand, some studies evaluated the transition of PCV-7 to PCV-13 [3] [4] [5] 41] . Conclusions drawn from the replacement of PCV-7 with PCV-13 ranged from borderline cost -effective (England) [41] to cost-saving (USA, Germany, Greece, and The Netherlands) [3] [4] [5] . Although there are lots of differences between our study and theirs, we share the same determination in evaluating the replacement of PCV-7 to PCV-13, as it is highly relevant to countries where PCV -7 has been offered under the national immunisation programme.
Our analysis is simple and straightforward based on the limited knowledge of epidemiology, and the assumption we made on efficacy or effectiveness of PCV-7 and PCV-13 may suggest an overestimation or underestimation of the results. However, evidences adopted are the best available ones to date, and assumptions made are the most conservative under the current uncertainty. The main limitations of our study are as follows: First, clinical evidences which show the effectiveness of vaccination in reducing annual incidence rates of the diseases in our model are adopted from studies carried out in other countries, since no similar study has been done in Japan. There should be differences in ethnicity as well as in the health system between those countries and Japan. Second, annual incidence rate of hospitalised pneumonia used in this study is based on a study done in only one prefecture because of the unavailability of national surveillance data, and such data would have a bias. Third, we did not include the benefits of vaccination in preventing antibiotic resistance in our model.
Including this benefit would bring more cost-effective results given that the serotypes identified as penicillin resistant and covered by PCV -7 is above 80% in Japan [8, 29] .
Conclusion
Our study finds that if PCV-13 had additional protection against AOM compared to PCV-7 and cost per PCV-13 shot is 1.7 times less than that of PCV -7, a PCV-13 vaccination programme offered to the birth cohort in Japan is likely to be a socially acceptable option compared to the current PCV -7 vaccination programme.
Furthermore, if cost per PCV-13 shot is 1.2 times less than that of PCV -7, replacing PCV-7 with PCV-13 will save money and gain more QALYs. However, if PCV -13 had no additional protection against AOM, the replacement can only be acceptable if cost per PCV-13 shot is 1.1 times less than of that of PCV-7. Due caution is needed in transferring these findings from our Japanese model to other health system, even so, replacing PCV-7 with PCV-13 to protect the birth cohort could be economically acceptable in developed countries. . Cost-effectiveness acceptability curves (CEACs) for Base-cases with/without care-giver's productivity loss CEAC is a commonly used visual aid for communicating the results of probabilistic sensitivity analysis in cost-effectiveness models, which presents relative cost-effectiveness as a function of the threshold ICER. The graphed value of any comparator at a particular willingness-to-pay represents the probability that it is cost-effective, based on the uncertainties included in the simulation.
